hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06314009 id: EH23-302 briefTitle: Beyond MARS: Magnetic Resonance Study: A Novel Assessment of Placental Perfusion During Pregnancy overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-12 date: 2026-12 date: 2024-03-15 date: 2024-03-15 name: NorthShore University HealthSystem class: OTHER briefSummary: The purpose of this study is to evaluate the flow of oxygen and blood necessary for nutrient transfer across the placenta during the second and third trimesters in pregnancy in women who are obese before pregnancy compared to women who have an average weight before pregnancy. This study will evaluate blood flow across the placenta by functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL). The investigators hypothesize that there will be differences in placental oxygenation and blood flow among women with obesity as compared to those with normal weight. Participants will be asked to complete Magnetic Resonance Imaging scans (MRIs), the first in the second trimester at 20-24 weeks and the second in the third trimester at 30-34 weeks. conditions: Placenta Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: functional Magnetic Resonance Imaging (fMRI) measure: Inter - rater reliability of assessing placental blood flow by arterial spin labeling (ASL) measure: Mean placental perfusion in second and third trimester measure: Mean R2* relaxation rates in second and third trimester measure: Perinatal outcomes including hypertensive disorders of pregnancy, gestational diabetes, preterm birth, small for gestational age, NICU admission, and stillbirth. sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06313996 id: CA082-011 id: 2023-507477-18 type: EUDRACT_NUMBER briefTitle: A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma overallStatus: NOT_YET_RECRUITING date: 2024-03-29 date: 2031-10-16 date: 2031-10-16 date: 2024-03-15 date: 2024-03-15 name: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company class: INDUSTRY name: Celgene Corporation briefSummary: The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma. conditions: Relapsed or Refractory Follicular Lymphoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: Cyclophosphamide name: Doxorubicin name: Vincristine name: Rituximab name: Prednisone name: Bendamustine name: Lenalidomide name: Fludarabine name: Liso-cel measure: Progression-free survival (PFS) measure: Complete response (CR) measure: Overall survival (OS) measure: Overall response (OR) measure: Duration of response (DOR) measure: Event-free survival (EFS) measure: Time to next anti-cancer therapy (TTNLT) measure: PFS rate measure: EFS rate measure: OS rate measure: Progression-free survival on the next line of treatment (PFS-2) measure: Number of participants with adverse events (AEs) measure: Number of participants with adverse event of special interest (AESIs) measure: Number of participants with serious adverse events (SAEs) measure: Number of participants with laboratory abnormalities measure: Frequency and length of hospitalizations measure: Number of participants with intensive care unit (ICU) inpatient days measure: Number of participants with non-ICU inpatient days measure: Mean change from baseline in key health-related quality of life (HRQoL) domains. measure: Time to meaningful improvement/deterioration in key HRQoL domains. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06313983 id: HM022BC3C01 briefTitle: A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer overallStatus: RECRUITING date: 2022-01-08 date: 2025-12 date: 2026-06 date: 2024-03-15 date: 2024-03-15 name: Tianjin Hemay Pharmaceutical Co., Ltd class: INDUSTRY briefSummary: The purpose of this study is to evaluate the effectiveness of Hemay022 combined with AI (exemestane or letrozole) in the treatment of ER+/HER2+ advanced breast cancer patients based on the progression-free survival (PFS) assessed by the independent review committee (IRC). The second purpose of this study is to evaluate the pharmacokinetics and efficacy of Hemay022 in combination with AI, and the safety of Hemay022 in combination with AI.
The trial plans to recruit 339 subjects, who will be randomly divided into two cohorts (the experimental group is hemay022 combined with AI, and the control group is lapatinib combined with capecitabine). During the treatment period, imaging examinations and anti-tumor efficacy evaluations will be performed regularly until the subject develop disease progression or starts receiving other treatments or dies or refuses to come to the hospital for follow-up or the trial is terminated, etc. conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 339 type: ESTIMATED name: Hemay022+AI name: Lapatinib+Capecitabine measure: Median progression-free survival（mPFS）based on IRC assessment according to RECIST v1.1 measure: Overall Survival (OS) of the two group according to RECIST v1.1 measure: Objective response rate ( ORR, partial response rate+ complete response rate) according to RECIST v1.1 measure: Clinical benefit rate (CBR) according to RECIST v1.1 measure: Duration of Response (DOR) according to RECIST v1.1 measure: Time to Response (TTR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing country: China name: Huiping Li role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06313970 id: QLMA-PC-IIT-001 briefTitle: First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-15 date: 2026-04-15 date: 2024-03-15 date: 2024-03-15 name: Fudan University class: OTHER briefSummary: This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: QL1706 name: Nab-paclitaxel name: Gemcitabine name: Bevacizumab measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Duration of Response (DoR) measure: Time to response(TTR) measure: Progression-free survival (PFS) measure: Overall survival（OS） measure: Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06313957 id: LB2302-0001 briefTitle: A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma overallStatus: RECRUITING date: 2024-03 date: 2026-09 date: 2028-09 date: 2024-03-15 date: 2024-03-15 name: Peking University Cancer Hospital & Institute class: OTHER briefSummary: This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma. conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 42 type: ESTIMATED name: LUCAR-20SP cells measure: Dose-limiting toxicity (DLT) rate measure: Incidence, severity, and type of treatment-emergent adverse events (TEAEs) measure: Recommended Phase 2 Dose (RP2D) regimen finding measure: Pharmacokinetics in peripheral blood measure: Pharmacokinetics in bone marrow measure: Objective Response Rate (ORR) after administration measure: Time to Response (TTR) after administration measure: Duration of Remission (DoR) after administration measure: Progression-free Survival (PFS) after administration measure: Overall Survival (OS) after administration measure: Incidence of anti-LUCAR-20SP antibody sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University Cancer Hospital & Institute status: RECRUITING city: Beijing state: Beijing zip: 100142 country: China name: Yuqin Song role: CONTACT phone: 13683398726 email: songyq22622@163.com name: Yan Xie role: CONTACT phone: 13671376201 email: xieyan9@263.net name: Yuqin Song role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06313944 id: GE-R-A-TPS briefTitle: German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation acronym: GE-R-A-TPS overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-10-01 date: 2026-10-01 date: 2024-03-15 date: 2024-03-15 name: Heinrich-Heine University, Duesseldorf class: OTHER name: Storz Medical AG briefSummary: This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores. conditions: Alzheimer Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Registry measure: Number of (Serious) Adverse Events measure: Number of adverse device effects measure: ADAS measure: Mini Mental State Examination (MMSE) baseline and follow- up measure: BDI-II measure: Clinical Dementia Rating Sum of Boxes Score (CDR-SB) measure: Alzheimer's Disease Cooperative Study/ Activities of Daily Living Scale (ADCS-ADL) measure: Numeric Rating Scale (NRS) for the main symptom sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06313931 id: UTI-IIDI-074-2023 briefTitle: Effects of Cognitive-motor Training on Cognition, Depression and Daily Functioning in Patients With Mild Cognitive Impairment (MCI) overallStatus: COMPLETED date: 2023-07-03 date: 2023-09-14 date: 2023-09-14 date: 2024-03-15 date: 2024-03-15 name: Universidad de Zaragoza class: OTHER briefSummary: This randomized controlled trial evaluated the effectiveness of an immersive virtual reality (IVR) application (focused on a daily activity) to train cognitive functions and its impact on depression and the ability to perform activities of daily living (ADL) in patients with mild cognitive impairment (MCI). With a dose of two sessions per week during six weeks, the study showed significant improvements in cognitive functions and reduction in depression, with notable effects in the experimental group. This underscores the potential of IVR as a valuable tool in the management of MCI. conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 26 type: ACTUAL name: cognitive training via immersive virtual reality name: cognitive training via paper and pencil name: motor stimulation measure: Spanish version of the Montreal Cognitive Assessment (MoCA-S) measure: Short Geriatric Depression Scale (SGDS-S) measure: Instrumental Activities of Daily Living Scale (IADL-S) sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: University of Zaragoza city: Teruel zip: 44003 country: Spain lat: 40.3456 lon: -1.10646 hasResults: False
nctId: NCT06313918 id: REK nr. 428096 briefTitle: Exercise Therapy in Mental Disorders-study overallStatus: RECRUITING date: 2023-09-27 date: 2026-09-26 date: 2026-09-26 date: 2024-03-15 date: 2024-03-15 name: Haukeland University Hospital class: OTHER briefSummary: The study will compare standard high-intensity training with brief high-intensity training in people with schizophrenia-spectrum or bipolar disorder. The overall aim is to determine which of the two is superior in a long-term perspective. conditions: Schizophrenia and Related Disorders conditions: Bipolar Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Open label, two-arm, parallel group, randomised trial, to compare standard and short HIT during 26 weeks of supervised exercise. The group will receive comprehensive follow-up to be able to carry out the 26 weeks exercise intervention program. Outcome measures will be taken at; baseline (T0), 4 weeks (T1), 12 weeks (T2), 26 weeks (T3), and 52 weeks (T4) post randomisation. primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: High intensity training (HIT) measure: Adherence measure: Change of the Simplified Negative and Positive Symptoms Interview (SNAPSI) score measure: Change of the Calgary Depression Scale in Schizophrenia score measure: Change of the Clinical Global Impression (CGI) score measure: Change of the Global Assessment of Funtioning (GAF) score measure: Change of quality of life (QOL10) score measure: Change of the International Physical Activity Questionaire (IPAQ) score measure: Change of the Brief Assessment of Cognition in Schizophrenia (BACS) score measure: Change of the Behavioural Regulation in Exercise Questionaire (BREQ) score measure: Change of the Difficulties in Emotion Regulation (DERS) score measure: Change in heart rate (beats per minute) measure: Change of maximal oxygene extraction (VO2max) measure: Change of level of inflammatory markers in blood measure: Change of body weight (kilograms) measure: Change of hip- and waist circumference (centimetres) measure: Change of serum glucose (mmol/L) measure: Change of serum cholesterols (mmol/L) measure: Change of serum triglyceride (mmol/L) measure: Change of gene expression measure: Change of methylation of DNA measure: Change of the Young Mania Rating Scale (YMRS) score sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Haukeland University Hospital status: RECRUITING city: Bergen zip: 5020 country: Norway name: Erik Johnsen, MD, PhD role: CONTACT phone: +47 55958400 email: erik.johnsen@helse-bergen.no name: Rune A Kroken, MD, PhD role: CONTACT phone: +47 55958400 email: rune.andreas.kroken@helse-bergen.no lat: 60.39299 lon: 5.32415 hasResults: False
nctId: NCT06313905 id: DRYLESS1 id: CHU La Rabta type: OTHER domain: La Rabta hospital briefTitle: EVADRY® in the Treatment of Xerostomia in Sjögren's Syndrome acronym: DRYLESS overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-12-31 date: 2025-12-31 date: 2024-03-15 date: 2024-03-15 name: University Tunis El Manar class: OTHER briefSummary: Xerostomia is a common and very bothersome manifestation that impairs the quality of life in Sjogren's syndrome. Symptomatic therapeutic alternatives for this syndrome are limited in Tunisia. We resort to bromhexine off-label with low efficacy. The aim of this work is to demonstrate the superiority of a treatment based on dietary supplements (EVADRY) vs placebo in the treatment of xerostomia. This is a double-blind randomized clinical trial with 2 arms: an EVADRY arm (n=90) and a placebo arm (n=90). The primary outcome measure is a 35% increase in salivary flow after 3 months. Secondary outcome measures were based on the Oral Health Impact Profile questionnaire, Xerostomia Inventory, the HAD depression scale, and the buccal Schirmer test. conditions: Sjogren's Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: double-blind randomized study primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: EVADRY name: Placebo measure: salivary flow rate (SFR) measure: Xerostomia Inventory in French version measure: Oral Health-related quality of life (OHIP-14) questionnaire measure: Hospital anxiety and depression (HAD) scale measure: Buccal Schirmer test sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06313892 id: PA24HD-2-05 briefTitle: The Effect of Home Based Tel-Exercise on Dialysis Patients overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-15 date: 2024-06 date: 2024-06 date: 2024-03-15 date: 2024-04-22 name: Pardis Specialized Wellness Institute class: OTHER briefSummary: The objective of the trial is to assess key areas of uncertainty regarding the use of synchronous home-based tele exercise in future practice and research, including issues relating to feasibility, safety and potential for efficacy. conditions: End Stage Renal Disease conditions: Hemodialysis Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomly allocate to intervention group or control group and will be examined in the same way. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: A research project collaborator who is not informed about grouping of participants will obtain outcome measurements of the functional test. Outcome adjudicators, and data analysts will be kept blinded to the allocation. Moreover, all investigators, staff, and participants will be kept masked to outcome measurements and trial results. whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: Home based Exercise measure: Recruitment rate measure: Retention rates measure: Adherence rate measure: Rate of changes of daily physical activity level measure: Rate of changes of Frailty level measure: Rate of changes of physical function level sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Khorshid Dialysis Center city: Isfahan country: Iran, Islamic Republic of lat: 32.65246 lon: 51.67462 facility: Pardis specialized wellness institute city: Isfahan country: Iran, Islamic Republic of lat: 32.65246 lon: 51.67462 hasResults: False
nctId: NCT06313879 id: PamukkaleU-SBE-SA-01 briefTitle: The Effect of Education Given to Parents of Children With Ventriculoperitoneal Shunt on Their Anxiety and Self-efficacy overallStatus: RECRUITING date: 2024-03-10 date: 2025-02 date: 2025-02 date: 2024-03-15 date: 2024-03-15 name: Pamukkale University class: OTHER briefSummary: This study aims to evaluate the effect of tele-education given to parents of children with ventriculoperitoneal shunt on their anxiety and self-efficacy. conditions: Hydrocephalus in Children studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups: comparative experiment and control primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: online education measure: State and Trait Anxiety Scale measure: General Self-Efficacy Scale sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Pamukkale University Hospital status: RECRUITING city: Denizli zip: 20180 country: Turkey name: Sevinç Aka role: CONTACT phone: +905057323842 email: sevincakaa@gmail.com lat: 37.77417 lon: 29.0875 hasResults: False
nctId: NCT06313866 id: 2024ZL368 briefTitle: the Clinical Effect of TCM Sniffing Therapy Combined With Electroacupuncture in PSCI overallStatus: RECRUITING date: 2023-12-20 date: 2024-12-01 date: 2025-02-01 date: 2024-03-15 date: 2024-03-15 name: Hangzhou Medical College class: OTHER briefSummary: The patients with cognitive impairment after stroke were divided into control group, electroacupuncture group, olfactory therapy group, and electroacupuncture combined with olfactory therapy group, with 35 people in each group. After the end of the treatment, the clinical efficacy was evaluated. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 140 type: ESTIMATED name: control name: Electronuchal acupuncture group treatment name: Smell therapy group treatment name: Electronuchal acupuncture combined with smell and inhalation therapy group treatment measure: MMSE measure: MoCA measure: MBI measure: TCD measure: Near-infrared functional imaging of the brain measure: Magnetic resonance scanning sex: ALL maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: the Affiliated Zhejiang Provincial People's Hospital to Hangzhou Medical College. status: RECRUITING city: Hangzhou state: Zhejiang zip: 311000 country: China name: Xinyun Dr LI, Doctor role: CONTACT phone: 8618069783240 email: lxyjasmine2010@163.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06313853 id: STUDY00007068 briefTitle: Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision acronym: COACH-Cog overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2027-03 date: 2027-09 date: 2024-03-15 date: 2024-03-15 name: University of Rochester class: OTHER name: National Institute on Aging (NIA) briefSummary: Building upon prior work, the investigator team developed a communication intervention for older adults with ADRD who are considering a decision about cancer management (adapted intervention: COACH-Cog). The investigators hypothesize that for patients with dual diagnoses of ADRD and cancer, COACH-Cog will increase autonomy support of care partners and patients in the decision-making process, leading to greater acknowledgement and support of cognitive concerns and cognitive-related goals, thereby improving goal concordant care. The investigators are conducting a pilot randomized controlled trial (RCT; cluster randomized by physician) including approximately 45 oncology clinicians and 130 patient/care partner dyads evaluating the effect of COACH-Cog on care partner and patient autonomy support, care partner well-being, goal-concordance, and communication. conditions: Cancer conditions: Dementia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Cluster-randomized primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 305 type: ESTIMATED name: COACH-Cog measure: Care Partner: Health Care Climate Questionnaire (HCCQ) measure: Montgomery Borgatta Caregiving Burden Scale measure: World Health Organization Quality of Life Brief Version (WHOQOL-BREF) measure: Care Partner PROMIS Depression measure: Care partner PROMIS Anxiety measure: Care partner: Patient-Centered Communication in Cancer Care (PCC-Ca) measure: Care partner: Health Care Climate Questionnaire - Age (HCCQ-Age) measure: Care partner: Qualitative assessment of goal concordance measure: Care partner: Decision Regret Scale measure: Patient: Patient-Centered Communication in Cancer Care (PCC-Ca) measure: Patient: Health Care Climate Questionnaire (HCCQ) measure: Patient: Health Care Climate Questionnaire - Age (HCCQ-Age) measure: Patient Decision Regret Scale measure: Physician Decision Regret Scale sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: University of Rochester Wilmot Cancer Institute city: Rochester state: New York zip: 14620 country: United States name: Allison Magnuson, DO, MS role: CONTACT email: Allison_magnuson@urmc.rochester.edu name: Jessica Bauer role: CONTACT email: JessicaC_Bauer@URMC.Rochester.edu lat: 43.15478 lon: -77.61556 hasResults: False